0
New
New
2022
Diabetes Therapeutics Market

Diabetes Therapeutics Market

by Product (Injectables, Oral antidiabetic Drugs): Global Opportunity Analysis and Industry Forecast, 2020-2030

✷  Report Code: A03202
Pages: 160
Apr 2022 | 15064 Views
Author(s) : Linu Dash, Prathmesh Bhasme , Onkar Sumant
Tables: 83
Charts: 49
  • Formats*:

  • Single User License, Five User
    License & Enterprise User License

  • Data Pack Excel License

  • It comes with the additional cost
    of $2500.00 contact sales.

 

 

The global diabetes therapeutics market was valued at $1,258.9 billion in 2020, and is projected to reach $3,390.0 billion by 2030, growing at a CAGR of 10.4% from 2021 to 2030.Diabetes is a chronic, metabolic disease characterized by elevated levels of blood glucose that cause serious damage to the heart, blood vessels, eyes, kidneys, and nerves. Diabetes therapeutics are medications used for the treatment of diabetes. They include human insulin analogues and oral-antidiabetic drugs (OAD). 

The COVID-19 outbreak is anticipated to have a negative impact on the growth of the diabetes therapeutics market. There was implementation of lockdown to control spread of COVID-19. Many hospitals were converted into COVID 19 centers due to which diabetics faced delays in treatment. For instance, according to the World Health Organization (WHO) report, as of December 19, 2021, over 273 million cases and over 5.3 million deaths have been reported globally. Furthermore, entire healthcare sector’s focus shifted toward COVID-19. Thus, COVID-19 adversely affected the growth of the diabetes therapeutics market.

The global diabetes therapeutics market size is majorly driven by increase in prevalence of diabetes, increase in sedentary lifestyle, and rise in prevalence of other chronic diseases such as hypertension. For instance, according to the International Diabetes Federation (IDF), it was reported that approximately 537 million adults (20-79 years) are living with diabetes, and the number of diabetic patients is projected to rise to 643 million by 2030 and 783 million by 2045. As a result, increase in prevalence of diabetes in population contributes to the diabetes therapeutics market growth. Furthermore, diabetes can be inherited and is linked to patients’ family history and genetics. It is not necessarily inherited by everyone, but people with family history are likely to develop diabetes. In addition, growth in awareness among population about self-management of diabetes contributes in the market growth. Moreover, development of affordable and effective diabetes therapeutics such as oral hypoglycemic agents and government initiatives to provide diabetes care facilities drive the growth of market.

Diabetes Therapeutics Market, Diabetes Therapeutics Market size, Diabetes Therapeutics Market share, Diabetes Therapeutics Market trends, Diabetes Therapeutics Market forecast, Diabetes Therapeutics Market growth, Diabetes Therapeutics Market opportunity

 

 For instance, Centers for Disease Control and Prevention (CDC) in the U.S. announced the launch of National Diabetes Prevention Program (National DPP), along with the partnership of public and private organizations. The program aims to prevent or delay type 2 diabetes. Furthermore, increase in number of diabetes centers globally contributes to the market growth. Diabetes centers provide diabetes care facilities to the patients. Furthermore, increase in geriatric population drives the growth of market. Older people are more prone to diabetes. For instance, according to Center for Aging Better, in 2021, there are almost 12 million people aged 65 and over in the UK, with 3.2 million aged 80 and over. Thus, presence of diabetes centers and increase in number of geriatric patients drive the growth of market. In addition, increase in diabetes causing factors such as family history, environmental factors, diet, obesity, and geography surge the growth of the market. Obesity is one of the major risk factors for developing diabetes. According to the World Population Review report, the U.S. has 36.20% obese adult population in 2022. Moreover, environmental factors such as polluted air, soil, water, vitamin-D deficiency, exposure to enteroviruses, and damage to immune cells are responsible for diabetes.

In addition, excessive sugar diet leads to incidence of diabetes. Moreover, advancements in diabetes diagnosis devices such as portable glucometer are driving the growth of diabetes diagnostics market. A glucometer is a small, portable machine that is used to measure blood glucose level and mainly used by diabetes patients. For instance, in February 2022, Ascensia Diabetes Care, a global diabetes care company, received U.S. Food and Drug administration (FDA) approval for its implantable, next-generation Eversense E3 continuous glucose monitoring (CGM) system. These standard and continuous glucose monitoring (CGM)  devices assist the diagnosis and therapy of diabetes. Hence, availability of such advanced glucose monitoring devices contributes in growth of market. Furthermore, increase in R&D activities for the development of novel diabetes treatments and new product approvals in market contributes in growth of diabetes market share by company. For instance, in July 2021, the U.S. Food and Drug Administration (FDA) approved Semglee (insulin glargine-yfgn) which is biosimilar to a reference product Lantus (insulin glargine), a long-acting insulin analog. Semglee is the first interchangeable biosimilar insulin product indicated to improve glycemic control in adults and pediatric patients with type 1 diabetes mellitus and in adults with type 2 diabetes mellitus. However, side effects associated with long-term use of anti-diabetes drugs impede the growth of this market.

Diabetes Therapeutics Market Segmentation

The diabetes therapeutics market is segmented on the basis of product and region. By product, the market is categorized into injectables and oral-antidiabetic drugs (OAD). The injectables therapy is further fragmented into insulin, glucagon-like peptide-1 (glp-1) receptor agonists/incretin, and amylinomimetic drugs. On the basis of oral-antidiabetic drugs (OAD), it is further segregated into prescription biguanides, sulfonylureas, thiazolidinediones, alpha-glucosidase inhibitors, dipeptidyl peptidase iv (dpp-4) inhibitors/gliptins, meglitinides, and sodium-glucose cotransporter-2 (sglt2) inhibitors/gliflozins.

Diabetes Therapeutics Market
By Product

Your browser does not support the canvas element.

Injectables segment held a dominant position in 2020 and would continue to maintain the lead over the forecast period.

Get more information on this report : Request Sample Pages

By region, the market is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Arabia, South Africa, and LAMEA).

The top 10 diabetes drugs key players operating in the global diabetes therapeutics market include Astrazeneca Plc., Boehringer Ingelheim GmbH, Eli Lilly and Company, Glaxosmithkline Plc., Johnson & Johnson, Merck & Co., Inc., Novartis Ag, Novo Nordisk, Sanofi S.A., and Takeda Pharmaceutical Company Limited.

Segment Review

Depending on therapy type, the injectables segment dominated the market in 2020, and this trend is expected to continue during the forecast period, owing to rise in prevalence of diabetes. However, the oral-antidiabetic drugs (OAD) segment is expected to witness considerable growth during the forecast period due to high prevalence of type-2 diabetes and affordability of oral-antidiabetic drugs (OAD) medication.

Depending on the region, North America garnered the major diabetes therapeutics market share in 2020, and is expected to dominate the diabetes therapeutics market forecast period, owing to rise in prevalence of diabetes, sedentary lifestyle, and well-established healthcare infrastructure such as presence of diabetes care centers in the region. However, due to increase in number of geriatric population, increase in prevalence of diabetes, and large population base, Asia-Pacific is expected to register the highest CAGR of 11.2% from 2021 to 2030.

Diabetes Therapeutics Market
By Region

2030
North America 
Europe
Asia-pacific
Lamea

North America was holding a dominant position in 2020 and would continue to maintain the lead over the analysis period.

Get more information on this report : Request Sample Pages

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the diabetes therapeutics market analysis from 2020 to 2030 to identify the prevailing diabetes therapeutics market opportunity.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the diabetes therapeutics market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global diabetes therapeutics market trends, key players, market segments, application areas, and market growth strategies.

Diabetes Therapeutics Market Report Highlights

Aspects Details
By Product
  • Injectables
  • Oral antidiabetic Drugs
By Region
  • North America  (U.S., Canada, Mexico)
  • Europe  (Germany, France, United Kingdom, Italy, Spain, Rest of Europe)
  • Asia-Pacific  (China, Japan, India, Australia, Rest Of Asia Pacific)
  • LAMEA  (Brazil, Saudi Arabia, South Africa, Rest of LAMEA)
Key Market Players ASTRAZENECA PLC, BOEHRINGER INGELHEIM GMBH, ELI LILLY AND COMPANY, GLAXOSMITHKLINE PLC, NOVARTIS AG, NOVO NORDISK, SANOFI S.A., TAKEDA PHARMACEUTICAL COMPANY LIMITED, johnson and johnson md&d, MERCK and CO., INC.
 

Loading Table Of Content...


 
 

In accordance with several interviews conducted with top-level CXOs, it can be inferred that rise in prevalence of diabetes and increase in awareness about diabetes in people drive the market growth.

Diabetes is caused due to variety of factors, including genetic, high-glucose diet, environmental factors, and obesity. Furthermore, rise in geriatric population contributes to the growth of market as older people are more prone to diabetes. However, side effects caused by anti-diabetes drugs are expected to restrict the market growth.

The oral-antidiabetic drugs (OAD) segment is expected to be lucrative for new entrants and existing market players, owing to increase in incidence of type-2 diabetes. Injectables such as human insulin analogues are used for the treatment of type-1 diabetes, an insulin-dependent diabetes.

The application of diabetes treatment is highest in North America, due to increase in prevalence of diabetes, presence of key players, and rise in disposable income among customers.

PURCHASE OPTIONS

Call or Email us

U.S.-Canada Toll-free: +1-800-792-5285
Int'l : +1-503-894-6022
Europe : + 44-845-528-1300
Email : help@alliedmarketresearch.com
 
FREQUENTLY ASKED QUESTIONS?

A. The total market value of diabetes therapeutics market is $1,258,936.4 million in 2020.

A. The top companies that hold the market share in diabetes therapeutics market are Astrazeneca Plc., Boehringer Ingelheim GmbH, Eli Lilly and Company, Glaxosmithkline Plc., Johnson and Johnson, Merck and Co., Inc., Novartis Ag, Novo Nordisk, Sanofi S.A., and Takeda Pharmaceutical Company Limited.

A. The market value of diabetes therapeutics Market in 2021 was $1,388,606.9 million

A. The base year for the report is 2020.

A. Yes, diabetes therapeutics companies are profiled in the report

A. The forecast period in the report is from 2021 to 2030

A. The key trends in the diabetes therapeutics market are increase in prevalence of diabetes, increase in sedentary lifestyle, and rise in prevalence of other chronic diseases such as hypertension

Looking for Customization?

 Customization Request

Have a Question?

 Speak with Analyst

Any Confusion?

 Inquire Before Buying

Have a glance of the Report

  Request Free Sample
RELATED TAGS
 

HAVE QUESTIONS?
SPEAK WITH ANALYST

 

DID YOU MISS ANYTHING?
DO YOU HAVE SPECIFIC REQUIREMENTS?

 

Download Free Sample

OR

Purchase Full Report of
Diabetes Therapeutics Market

Start reading instantly.
This Report and over 18,758+ more Reports, Available with Avenue Library. T&C*.

  • Online Only
  • $3,456
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  • Free industry update
    (Within 180 days)
  • Free report update in next update cycle
    (Apr 2023 - Apr 2024)
  • Data Pack
  • $3,840
  • Restricted to one authorized user
  • One print only
  • Available in
    Excel
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
    (Apr 2023 - Apr 2024)
  • Single User
  • $5,769
  • Restricted to one authorized user
  • One print only
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
    (Apr 2023 - Apr 2024)
  • Five Users
  • $6,450
  • Limited to five authorized users
  • Print upto five copies
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
    (Apr 2023 - Apr 2024)
  • Enterprise
    License/PDF

  • $10,995
  • Unlimited
    within
    company/enterprise
  • Available in Excel & PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
    (Apr 2023 - Apr 2024)
  • Library
    Membership

  • $ 999
    Per User/ Per month/ Billed annually
  • Published Content
    E-access
  • Company Profiles
    E-access
  • Newly Added Content Access
  • 10 PDF
    Downloads
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

Get Industry Data Alerts

Why Allied Market Research?

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers